NOT KNOWN FACTUAL STATEMENTS ABOUT AZ-23

quinupristin/dalfopristin will increase the amount or impact of avanafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. CYP3A4 inhibitors could lower avanafil clearance rising systemic exposure to avanafil; amplified stages may well cause improved related adverse events; the utmost suggested dose of STENDRA is fifty